Literature DB >> 24367163

Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer.

Erin M Bertino1, Bhuvaneswari Ramaswamy1.   

Abstract

Advanced breast cancer represents a therapeutic challenge for oncologists. Chemotherapy with anthracyclines and taxanes has improved survival in this setting, but resistant and refractory disease is common. Ixabepilone, an epothilone, is a recently approved chemotherapeutic agent, both as a single agent and in combination with capecitabine, with efficacy in patients with resistant advanced disease. In this review, the distinctive properties of this drug are discussed, as well as the clinical evidence of efficacy. Ongoing clinical trials are exploring the role of ixabepilone in several clinical settings: neoadjuvant, adjuvant, and novel combinations.

Entities:  

Keywords:  chemotherapy; metastatic disease; neoadjuvant chemotherapy; solid tumor

Year:  2010        PMID： 24367163      PMCID： PMC3846877          DOI： 10.2147/bctt.s5430

Source DB:  PubMed          Journal:  Breast Cancer (Dove Med Press)        ISSN： 1179-1314


  44 in total

1.  E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.

Authors:  Kathy D Miller
Journal:  Clin Breast Cancer       Date:  2003-02       Impact factor: 3.225

Review 2.  Chemotherapy: what progress in the last 5 years?

Authors:  Anne Hamilton; Gabriel Hortobagyi
Journal:  J Clin Oncol       Date:  2005-03-10       Impact factor: 44.544

Review 3.  Peripheral neuropathy induced by microtubule-stabilizing agents.

Authors:  James J Lee; Sandra M Swain
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

4.  Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.

Authors:  Mutlu Demiray; Ender Kurt; Turkkan Evrensel; Ozkan Kanat; Murat Arslan; Ozlem Saraydaroglu; Ilker Ercan; Guzin Gonullu; Sehsuvar Gokgoz; Ugur Topal; Sahsine Tolunay; Ismet Tasdelen; Osman Manavoglu
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

5.  Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.

Authors:  J Bonneterre; M Spielman; J P Guastalla; M Marty; P Viens; P Chollet; H Roché; P Fumoleau; L Mauriac; H Bourgeois; M Namer; J P Bergerat; J L Misset; L Trandafir; M Mahjoubi
Journal:  Eur J Cancer       Date:  1999-10       Impact factor: 9.162

6.  Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.

Authors:  Francis Y F Lee; Richard Smykla; Kathy Johnston; Krista Menard; Kelly McGlinchey; Russell W Peterson; Amy Wiebesiek; Gregory Vite; Craig R Fairchild; Robert Kramer
Journal:  Cancer Chemother Pharmacol       Date:  2008-03-19       Impact factor: 3.333

Review 7.  Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.

Authors:  Charles Dumontet; Mary Ann Jordan; Francis F Y Lee
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

8.  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

Authors:  Eva Thomas; Josep Tabernero; Monica Fornier; Pierfranco Conté; Pierre Fumoleau; Ana Lluch; Linda T Vahdat; Craig A Bunnell; Howard A Burris; Patrice Viens; José Baselga; Edgardo Rivera; Valentina Guarneri; Valerie Poulart; Judith Klimovsky; David Lebwohl; Miguel Martin
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544

9.  Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.

Authors:  Neelima Denduluri; Jennifer A Low; James J Lee; Arlene W Berman; Janice M Walshe; Ujala Vatas; Catherine K Chow; Seth M Steinberg; Sherry X Yang; Sandra M Swain
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544

10.  The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.

Authors:  Sanjay Goel; Marvin Cohen; S Nilgün Cömezoglu; Lionel Perrin; François André; David Jayabalan; Lisa Iacono; Adriana Comprelli; Van T Ly; Donglu Zhang; Carrie Xu; W Griffith Humphreys; Hayley McDaid; Gary Goldberg; Susan B Horwitz; Sridhar Mani
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 13.801
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.